Recruiting for Phase 1/2 Study

We are currently recruiting for a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SPG302 in healthy volunteers and ALS participants.

The trial is open in Australia and soon to be in the USA. The FDA has approved the U.S. IND (IND 154637) and granted Orphan Drug Designation for SPG302 for the treatment of ALS.

Upcoming U.S. Clinical Trials

Status: not yet recruiting; please continue to check the status at

Boston, Massachusetts at Mass General Brigham

Contact: Mary C McCormick

For additional information, visit

Clinical Trial Sites are Open in Australia:

Status: Recruiting

Dr. Schultz at Flinders Medical Center in Adelaide, SA.  

Contact: Dr. David Schultz at Flinders Medical Center

Dr Henderson at the Royal Brisbane and Woman’s Hospital in Brisbane, Queensland

Contact: Sue Heggie at Royal Brisbane and Woman’s Hospital

Dr Rowe at Macquarie Hospital in North Ryde, N.S.W.

Contact: Richard Gan at Macquarie